Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 10/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 6/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 7/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.35 |
| ▸ | DPP8 | Q6V1X1 | 4/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899756 | 0.90 | HTR2A (0.41) | — | |
| SCHEMBL5899751 | 0.87 | DPP4 (0.37) | DPP4DPP7DPP9DPP8SIGMAR1 | |
| SCHEMBL5899659 | 0.84 | TAAR1 (0.44) | ALDH1A1 | |
| SCHEMBL5899598 | 0.81 | TAAR1 (0.40) | FFAR4 | |
| SCHEMBL5899766 | 0.80 | TAAR1 (0.45) | SLC6A2SLC6A4 | |
| SCHEMBL5899805 | 0.80 | FFAR4 (0.36) | DPP4SIGMAR1FFAR4 | |
| SCHEMBL5899791 | 0.79 | TRPA1 (0.40) | DPP4DPP7SIGMAR1ALDH1A1 | |
| SCHEMBL5899599 | 0.79 | FFAR4 (0.33) | FFAR4 | |
| SCHEMBL5899760 | 0.77 | TAAR1 (0.34) | SLC6A2SLC6A4SIGMAR1FFAR4 | |
| SCHEMBL5899802 | 0.74 | SLC1A2 (0.42) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7030267-B2 | Cycloproply β-amino acid derivatives | WARNER-LAMBERT COMPANY, LLC (US) | 2006-04-18 | — | — | US | disclosed |
| EP-1592661-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | Warner-Lambert Company LLC (US) | 2005-11-09 | — | — | EP | disclosed |
| WO-2004065361-A2 | CYCLOPROPYL BETA-AMINO ACID DERIVATIVES | WARNER-LAMBERT COMPANY LLC (US) | 2004-08-05 | — | — | WO | disclosed |
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | SCHWARZ JACOB BRADLEY (US) | 2004-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147608-A1 | Cyclopropyl beta-amino acid derivatives | CACNA1S, CACNA1D, CACNA1B | DPP4 1351/4885DPP7 1567/4885DPP9 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.